SRX.AX : Summary for SIRTEX MED FPO - Yahoo Finance

U.S. Markets open in 8 hrs 32 mins

Sirtex Medical Limited (SRX.AX)


ASX - ASX Delayed Price. Currency in AUD
Add to watchlist
17.44-0.34 (-1.91%)
As of 3:38PM AEDT. Market open.
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close17.78
Open17.80
Bid17.42 x
Ask17.44 x
Day's Range17.39 - 17.80
52 Week Range12.20 - 35.04
Volume289,071
Avg. Volume526,981
Market Cap1.01B
Beta1.73
PE Ratio (TTM)20.91
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield0.31 (2.28%)
Ex-Dividend DateN/A
1y Target EstN/A
  • Sirtex Medical Ltd. :SRX-AU: Earnings Analysis: For the six months ended December 31, 2016 : March 20, 2017
    Capital Cube3 days ago

    Sirtex Medical Ltd. :SRX-AU: Earnings Analysis: For the six months ended December 31, 2016 : March 20, 2017

    Categories: Yahoo Finance Get free summary analysis Sirtex Medical Ltd. reports financial results for the half-year ended December 31, 2016. We analyze the earnings along side the following peers of Sirtex Medical Ltd. – Starpharma Holdings Limited, Clinuvel Pharmaceuticals Limited and Alchemia Limited (SPL-AU, CUV-AU and ACL-AU) that have also reported for this period. Highlights Summary numbers: Revenues ... Read more (Read more...)

  • Capital Cube3 months ago

    ETFs with exposure to Sirtex Medical Ltd. : December 12, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to Sirtex Medical Ltd. Here are 5 ETFs with the largest exposure to SRX-AU. Comparing the performance and risk of Sirtex Medical Ltd. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Business Wire3 months ago

    NCCN Guidelines® Recommend SIR-Spheres® Y-90 Resin microspheres for the Treatment of Metastatic Colorectal Cancer

    Sirtex Medical Limited today announced that SIR-Spheres® Y-90 resin microspheres has been included as a Category 2A recommended treatment in the latest National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology for colon cancer and rectal cancer.